+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

P

Actively Recruiting

This research aims to evaluate the safety and effectiveness of different light doses in treating adults aged 18 to 75 with Port-Wine Birthmarks PWB. The study is a multi-center, randomized, double-blind, vehicle-controlled Phase 2 trial conducted in two sequential stages. It focuses on comparing Hemoporfin photodynamic therapy PDT with a vehicle placebo control using fixed drug dosing and varying light fluences. Participants will be randomly assigned to receive either Hemoporfin PDT or vehicle PDT via intravenous infusion at a fixed dose of 5 mgkg. They will undergo fixed laser irradiation for a set time in cycles lasting 8 weeks. Each participant may receive up to three treatment cycles. The study consists of a Screening Period, Treatment Period, efficacy evaluation for subsequent treatment, and an End of Study phase, lasting up to approximately 44 weeks. Throughout the study, participants will be closely monitored for local and systemic adverse events. Researchers will assess changes in PWB severity using the Port Wine Birthmark-Investigator Global Assessment PWB-IGA scale and other measures from baseline until the studys end. Regular evaluations include physical exams, safety assessments, and efficacy reviews, ensuring participant health and adherence over the entire study duration.

Age: 18Years - 75YearsAll GendersPhase 2
5 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are conducting a phase 3 clinical trial to study adults with moderate or severe abdominal subcutaneous fat. The trial aims to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared to a placebo in reducing abdominal fat. Approximately 320 participants will be enrolled to better understand how well this treatment works and how safe it is for reducing fat under the skin in the abdominal area. Participants will be randomly assigned to receive either the CBL-514 injection or a placebo 0.9% Sodium Chloride solution. Each participant can receive up to four treatments, with injections administered subcutaneously to the abdomen at four-week intervals. Both groups will receive up to 120 mL per treatment, delivered through 50 injections each time. During the study, participants will undergo assessments including patient and clinician reports on abdominal fat levels, measured from the start of the study to four weeks after the final treatment. Researchers will monitor changes in abdominal fat and improvements on rating scales. Participants will also be evaluated for safety and tolerability throughout the trial, which is expected to last until September 2027.

Age: 18Years +All GendersPhase 3
13 locations
E

Actively Recruiting

Researchers are evaluating how well tilrekimig works, its safety, and effects on the body in adults and adolescents aged 12 years and older with moderate to severe atopic dermatitis, a skin condition causing dryness, itching, and redness. The study includes participants who have had atopic dermatitis for at least one year and have not responded well to topical medicines. The trial is a Phase 3 randomized, double-blind study comparing tilrekimig, dupilumab, and placebo. Participants will receive subcutaneous injections during a 24-week initial treatment period, randomized in a 221 ratio to tilrekimig, dupilumab, or placebo. This is followed by a 28-week maintenance period where study drugs continue until the last dose at week 48. Some participants may join a long-term extension study at week 52 to further evaluate treatment effects and safety, while others will enter a 12-week safety follow-up period after their last dose. During the trial, participants will have regular visits for assessments including skin evaluations using the Eczema Area and Severity Index EASI and Investigator Global Assessment scales. Other measures include patient-reported skin itch severity and quality of life questionnaires. Safety is monitored through adverse event tracking, vital signs, and laboratory tests, with follow-up continuing for at least 16 weeks after the last dose. The total study participation lasts up to 64 weeks, including treatment and follow-up periods.

Age: 12Years +All GendersPhase 3
32 locations
L

Actively Recruiting

This research evaluates the long-term safety and effectiveness of YCANTH also known as VP-102 or TO-208 in people who have common warts and previously participated in related studies COVE-2 or COVE-3. The study aims to monitor side effects, especially local skin reactions, and to assess how well continued application of YCANTH clears warts over time. Participants with warts will receive up to four additional treatments of YCANTH applied to each wart every 21 days, with the option to pause if skin reactions occur. Clear warts are covered with occlusive tape overnight after treatment. If new warts appear after clearance, treatment resumes. Participants without warts attend observation visits every 42 days. Those with remaining warts after four treatments may discontinue and seek other therapies. Throughout the study, participants will attend visits up to day 378, including treatment and observation periods. Researchers will assess adverse events, vital signs, medication use, and wart clearance at each visit. Treatments involve wart paring if needed before drug application. The study tracks safety and wart reduction until the final visit nearly a year after starting this follow-up phase.

Age: 2Years +All GendersPhase 3
12 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations